Home > Insider Trading > Filing (0001209191-21-055485)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1087294	Cumberland Pharmaceuticals Inc	CPIX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1632384	C Joseph Galante	2525 West End Avenue Suite 950 Nashville TN 37203		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-08-02	142	$3.34	34,973	No	4	P	Direct
Common Stock	Acquisiton	2021-08-03	142	$3.17	35,115	No	4	P	Direct
Common Stock	Acquisiton	2021-08-04	142	$3.18	35,257	No	4	P	Direct
Common Stock	Acquisiton	2021-08-05	142	$3.11	35,399	No	4	P	Direct
Common Stock	Acquisiton	2021-08-06	142	$3.01	35,541	No	4	P	Direct
Common Stock	Acquisiton	2021-08-09	142	$2.93	35,683	No	4	P	Direct
Common Stock	Acquisiton	2021-08-10	142	$2.96	35,825	No	4	P	Direct
Common Stock	Acquisiton	2021-08-11	142	$2.98	35,967	No	4	P	Direct
Common Stock	Acquisiton	2021-08-13	142	$2.92	36,109	No	4	P	Direct
Common Stock	Acquisiton	2021-08-16	142	$2.92	36,251	No	4	P	Direct
Common Stock	Acquisiton	2021-08-17	142	$3.05	36,393	No	4	P	Direct
Common Stock	Acquisiton	2021-08-18	142	$2.97	36,535	No	4	P	Direct
Common Stock	Acquisiton	2021-08-19	142	$3.02	36,677	No	4	P	Direct
Common Stock	Acquisiton	2021-08-20	142	$2.96	36,819	No	4	P	Direct
Common Stock	Acquisiton	2021-08-23	142	$2.87	36,961	No	4	P	Direct
Common Stock	Acquisiton	2021-08-24	142	$2.89	37,103	No	4	P	Direct
Common Stock	Acquisiton	2021-08-25	142	$2.79	37,245	No	4	P	Direct
Common Stock	Acquisiton	2021-08-26	142	$2.82	37,387	No	4	P	Direct
Common Stock	Acquisiton	2021-08-27	142	$2.84	37,529	No	4	P	Direct
Common Stock	Acquisiton	2021-08-30	142	$2.88	37,671	No	4	P	Direct
Common Stock	Acquisiton	2021-08-31	142	$2.93	37,813	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.